For the past two years, GLP-1 therapies have dominated headlines, investor calls, and clinical conversations alike. What began as a breakthrough in metabolic science has rapidly evolved into one of the most commercially significant drug classes in history. But as the market enters its next phase, the defining question is shifting. It is no longer about whether these therapies work, but how they are accessed, delivered, and sustained over time.
Increased access is not the same as better care, and in many cases, it may be fragmenting it.
From breakthrough to infrastructure
The clinical case for GLP-1 is now well established. With weight loss outcomes exceeding 15% in clinical trials such as SURMOUNT-5, and growing evidence across cardiovascular, renal and metabolic conditions, these therapies are increasingly positioned not as niche interventions, but as foundational tools in chronic disease management.
At the same time, innovation continues at pace. Oral GLP-1s promise to remove key barriers to uptake, while next-generation therapies push efficacy even further. The pipeline is expanding beyond weight loss toward broader, “whole-body” indications.
But as the science matures, differentiation at the molecule level is becoming only part of the story.
The more profound shift is structural. Obesity is no longer being treated as a short-term intervention, but as a chronic, relapsing disease requiring continuous management. That shift demands more than effective drugs. It requires systems that can support patients over time; across initiation, adherence, and maintenance.
In other words, we are moving from a moment of innovation to one of infrastructure.
Expanding access, increasing fragmentation
Access to GLP-1 therapies is expanding rapidly, but not in a coordinated way.
Patients can now obtain the same medication through multiple pathways: primary care, specialist clinics, manufacturer-led programs, digital health platforms, retail providers, and telehealth services. The expected arrival of off-patent semaglutide, alongside compounded and personalized alternatives, will only accelerate this trend.
On the surface, this looks like progress. Barriers are lowering. Convenience is increasing. New patient populations are entering the market.
But underneath, a more complex reality is emerging.
Each access pathway comes with different pricing structures, levels of clinical oversight, and degrees of support. Patients are increasingly navigating these options themselves, often switching between providers, platforms, or products based on cost, availability, or convenience.
The result is not just expanded access, but fragmented care.
In a chronic condition like obesity, fragmentation carries real consequences. Continuity of care becomes harder to maintain. Accountability for outcomes becomes blurred. Adherence (already a known challenge) becomes even more fragile.
In this new landscape, the risk is not under-treatment, but uncoordinated treatment.
The next battleground: long-term care
As access expands, the competitive focus is beginning to shift.
The first phase of the GLP-1 market was defined by initiation: getting patients onto therapy. The next phase will be defined by what happens after.
Obesity is a lifelong condition, and discontinuation of treatment often leads to weight regain, as shown in studies following semaglutide withdrawal. This makes long-term adherence the central challenge-and what ultimately determines value.
Several dynamics are converging here.
Lower-cost, off-patent semaglutide may play a growing role as maintenance therapies, while newer, higher-efficacy drugs compete for initial acute weight loss. Oral formulations could improve persistence by reducing fricting in long-term use. At the same time, attention is shifting toward the quality of weight loss, with increasing focus on muscle preservation and overall metabolic health; a trend reflected in the growing pipeline of muscle-preserving obesity therapies (see Figure 1).
FIGURE 1: Innovation is shifting toward preserving lean muscle mass, a critical factor for long-term outcomes. Source: IQVIA Analytics Link; Clinicaltrials.gov; company reports, press releases, IQVIA Thought Leadership desk research and analysis
Together, these trends point toward a more stratified model of care; one where treatment is tailored not only to clinical profile, but also to patient preference, affordability, and ability to sustain therapy over time.
This is where the real competition begins.
In a fragmented ecosystem, prescribing the drug is only the starting point. The harder challenge is keeping patients on it, supporting them throughout their journey and ensuring that outcomes are sustained beyond the initial intervention.
What comes next?
The GLP-1 market is entering a phase where infrastructure will determine impact.
Pharmaceutical companies are no longer just competing on efficacy, but on how effectively their therapies are embedded within broader care models. Digital platforms, providers, pharmacies and payers are all becoming critical actors in shaping the patient journey.
This raises a fundamental strategic question: who owns the patient relationship?
As distribution channels multiply, control over the patient experience becomes more diffuse. And with it, so does the ability to influence adherence, outcomes, and long-term value.
For patients, the promise is real: more choice, faster access, and therapies that extend beyond weight loss. But without coordination, the same abundance of options risks creating confusion, inconsistency, and drop-off over time.
The next winners in obesity care will not be those who simply deliver the most effective drugs, but those who design access models that deliver continuity, accountability, and sustained outcomes.
In the end, the question is no longer who can start treatment, but who can make it last.
If you’d like to explore these themes further, we’ve covered additional angles shaping the GLP-1 landscape:
→ The longevity question: Should healthy people be taking GLP-1s preventively? Watch
→ The adherence crisis: Only 8% stay on treatment after three years. What's the fix? Watch
→ The access puzzle: Who pays when a drug costs $1,000/month, and coverage is collapsing? Watch